HTR3A and irritable bowel syndrome: Recently, novel mixed 5-HT1A agonists/5-HT3 antagonists, 5-HT1B/D agonists, and 5-HT2B antagonists have been proposed as new therapeutics for IBS (Tack et al., 2000; Mulak and Paradowski, 2006; Vera-Portocarrero et al., 2008; Asagarasu et al., 2009; O’Mahony et al., 2010b).